Welcome to our dedicated page for HALOZYME THERAPEUTICS SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Halozyme Therapeutics, Inc. filings document the company's drug-delivery business, royalty-based collaboration model, governance actions and capital-market disclosures. 8-K reports cover financial results and guidance, executive officer appointments and compensation arrangements, bylaw amendments, and annual meeting voting results.
Proxy materials describe board elections, executive compensation, equity awards, auditor ratification and stockholder voting mechanics. Filings also provide formal disclosure around ENHANZE, Hypercon and Surf Bio technology portfolio updates, partnered commercial products, and acquisition-related operating updates when reported by the company.
Halozyme Therapeutics Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 6,173,547 shares of Common Stock, representing 5.21% of the class as reported for the period ending 03/31/2026. The filing shows sole dispositive power of 6,173,547 shares and sole voting power of 902,329 shares. The filing is signed by Ashley Grim on 04/30/2026.
Halozyme Therapeutics has appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026, succeeding interim CFO David Ramsay, who will move to an advisory role during a brief transition. Snellgrove brings more than 30 years of finance leadership, most recently serving as Vice President, Investor Relations and previously as CFO of Johnson & Johnson’s Pharmaceuticals sector.
His compensation includes a $670,000 annual salary, a target bonus equal to 50% of salary (prorated for 2026), and a minimum $4,000,000 long-term incentive award in 2027. Upon joining, he will receive equity awards with a total grant date value of $7,200,000, split between $3,200,000 in restricted stock units that vest over three years and $4,000,000 in stock options vesting over four years under the 2021 Stock Plan, plus a $350,000 sign-on cash bonus subject to partial repayment if he leaves or is terminated for misconduct within 24 months.
Halozyme Therapeutics, Inc. has amended its Bylaws following approval by the Board of Directors on April 22, 2026. Directors may now be removed at any time, with or without cause, by holders of a majority of shares entitled to vote in director elections.
The amendment also clarifies that stockholder actions that would otherwise be taken at an annual or special meeting may not be taken without a meeting, aligning the Bylaws with Article FIFTH of the Company’s Certificate of Incorporation. The full amended Bylaws are provided as Exhibit 3.1.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley exercised stock options for 10,000 shares of common stock at an exercise price of $12.070 per share on April 6, 2026. The options were part of a grant dated February 22, 2017 with a ten-year term.
On the same date, she sold a total of 10,000 common shares in open-market transactions at weighted average prices of $63.139 and $64.015 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she directly holds 767,780 common shares.
RAMSAY DAVID A reported acquisition or exercise transactions in this Form 4 filing.
HALOZYME THERAPEUTICS, INC. reported that interim CFO David A. Ramsay received a grant of 10,000 Restricted Stock Units tied to the company’s common stock. These RSUs were awarded as compensation rather than through an open-market purchase or sale.
The award vests in full on June 30, 2026, provided he remains employed through that date. After vesting, the shares are subject to a one-year holding period, meaning he must continue to hold the resulting shares for an additional year. Following this grant, his directly held RSU-related position from this award is 10,000 units.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported an exercise-and-sell transaction in company stock. On April 1–2, she exercised options to acquire a total of 40,000 shares of common stock at an exercise price of $12.0700 per share, from options with a ten-year term expiring in February 2027.
Over the same two days, she sold 40,000 shares of common stock in open-market trades at per-share prices including $65.3580, $65.7140, $64.0630 and $64.8870. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, she directly owned 767,780 shares of Halozyme common stock.
Halozyme Therapeutics received an amended Schedule 13G/A from The Vanguard Group reporting that Vanguard beneficially owns 0 shares of Halozyme common stock, representing 0% of the class. The filing explains Vanguard underwent an internal realignment and certain subsidiaries will report disaggregated holdings in accordance with SEC Release No. 34-39538 (January 12, 1998). The amendment is dated 03/13/2026 with a signature dated 03/27/2026. The filing states Vanguard's subsidiaries pursue the same investment strategies and that no single other person’s interest exceeds 5%.
HALOZYME THERAPEUTICS, INC. filed an initial ownership report for Interim CFO David A. Ramsay. This Form 3 shows his status as an officer but does not list any equity transactions or holdings in the provided data. It is an administrative disclosure of insider status rather than a trading event.